

indolyloxy)-2-propanol or (2S)-(-)-3-[4-(6-trifluoromethyl-3-indolyl)piperidin-1-yl]-1-(4-indolyloxy)-2-propanol or a pharmaceutically acceptable salt thereof.

26. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound of Claim 1.


27. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound of Claim 2.

28. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound of Claim 8.

29. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound of Claim 13.

30. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound of Claim 14.

31. ^{use of} A method of affecting the serotonin 1A receptor which comprises administering to a subject in need of such treatment an effective amount of a compound of the formula



XII


wherein r is 0-4;
s is 0-1;

D is a residue which combines with the carbon atoms to which it is attached to complete a pyrrolyl, imidazolyl, pyridinyl, pyrazinyl, pyridazinyl or pyrimidinyl group;

wherein X is hydrogen, phenyl, hydroxy or methoxy;
provided that X is hydrogen or phenyl when r is 0;

-210-

R is




the dotted line is an optional double bond;

R¹ is piperidiny1, adamantyl, piperazino, morpholino or pyrrolyl,

substituted with 0-1 phenyl or benzyl group or 0-4 C₁-C₃ alkyl, C₁-C₃ alkoxy or halo groups;

which phenyl or benzyl group is substituted with 0-2 C₁-C₃ alkyl, halo, trifluoromethyl or C₁-C₃ alkoxy groups;

or R¹ is



VI

n and m are independently 4-5, and the group of Formula VI may be substituted with 0-1 oxo group and 0-2 C₁-C₃ alkyl, C₁-C₃ alkoxy or halo groups;

or R¹ is C₁-C₄ alkyl,

substituted with pyrrolyl, adamantyl, furyl, thienyl, pyridinyl, morpholinyl, piperidiny1, tetrahydropyrrolyl, piperazinyl, tetrahydrofuryl, benzazepinyl, dibenzazepinyl or quinolinyl,

substituted with 0-4 C₁-C₃ alkyl, C₁-C₃ alkoxy or halo groups;

-211-

R² is hydroxy, hydrogen, cyano, C₁-C₄ alkyl, or (phenyl or benzyl substituted with 0-2 C₁-C₃ alkyl, C₁-C₃ alkoxy or halo groups);

or R² is amino substituted with phenyl or benzyl,

5 substituted with 0-2 C₁-C₃ alkyl, C₁-C₃ alkoxy, halo or trifluoromethyl groups;

or R² is absent when the dotted line is a double bond;

R³ is C₁-C₄ alkyl,

substituted with 0-2 phenyl groups,

10 substituted with 0-2 C₁-C₃ alkyl, C₁-C₃ alkoxy or halo groups;

or R³ is C₁-C₄ alkyl substituted with hydroxyimino or hydroxy;

or R³ is phenoxy,

15 substituted with 0-1 methylenedioxy or substituted with 0-2 C₁-C₃ alkyl, C₁-C₃ alkoxy, trifluoromethyl or halo groups;

or R³ is dibenzocycloheptenyl, benzodioxolyl, benzodioxinyl, or dibenzocyclohexenyl;

20 or R³ is phenyl, naphthyl, tetralinyl, tetrazolyl, benzimidazolyl, indolyl, benzofuryl, benzothienyl, piperidino or morpholino,

substituted with 0-2 C₁-C₃ alkyl, C₁-C₃ alkoxy, C₄-C₈ cycloalkylalkoxy, halo, nitro, trifluoromethyl,

25 difluoromethyl, hydroxy or trifluoromethoxy groups;

or substituted with 0-1 phenyl, piperidinonyl,

hexahydropyridazinonyl or piperazinonyl group,

substituted with 0-2 C₁-C₃ alkyl, oxo, C₁-C₃

alkoxy, halo or trifluoromethyl groups;

30 or R² and R³ combine to form C₁-C₄ alkylidene,

substituted with 0-2 phenyl groups,

substituted with 0-2 C₁-C₃ alkyl, C₁-C₃ alkoxy,

halo or trifluoromethyl groups;

R⁵ is C₁-C₆ alkyl or C₁-C₄ acyl;

35 or R⁵ is C₁-C₃ alkyl substituted with phenyl, benzodioxinyl or benzodioxolyl,


-212-

substituted on the phenyl ring with 0-2 C₁-C₃ alkyl, C₁-C₃ alkoxy or halo groups;

or R⁵ is pyridinyl, phenyl, naphthyl, tetralinyl, pyrimidinyl, indolyl, benzofuryl, benzothienyl, pyrazinyl,

5 quinolinyl, isoquinolinyl, pyridazinyl or quinazolinyl, substituted with 0-2 C₁-C₃ alkyl, trifluoromethyl, C₁-C₃ alkoxy or halo groups;

or R⁵ is



VII


B is oxygen or sulfur;

Y is a residue which combines with the atoms to which it is
15 attached to complete a triazolyl, imidazolyl, thiazolyl or pyrrolyl ring;

A is a residue which combines with the nitrogen atom to which it is attached to complete

a) an azabicyclo(octyl, nonyl or decyl) group;


b)



VIII

-213-


c)



5

or

d)



10

M is a residue which combines with the carbon atom to which it is attached to complete an indanyl, indenyl, pyrrolidinyl, tetralinyl, benzopyranyl, dihydroindolyl, naphthodihydrofuranyl, benzodihydrothienyl, benzodihydrofuranyl, benzodihydropyranyl, naphthodihydrothienyl, or naphthodihydropyrrolyl group wherein the spiro junction is not to an aromatic ring,

substituted with 0-2 C₁-C₃ alkyl, oxo, C₁-C₃ alkoxy, pyrrolidinyl- or piperidinyl-C₁-C₃ alkoxy, C₁-C₂ alkylendioxy, phenoxy, benzyloxy, phenyl or halo groups;

p represents 0-2;

R⁶ and R⁷ independently represent phenyl groups, substituted with 0-2 C₁-C₃ alkyl, C₁-C₃ alkoxy or halo groups;

or R⁶ and R⁷ combine with the atom to which they are attached to complete a fluorenyl or dihydroanthracenyl group;

-214-

or R⁶ and R⁷ represent hydrogen, provided that p must not be 1;

q represents 0-2;

Q represents a residue which combines with the atoms to which it is attached to complete a phenyl or naphthyl group, substituted with 0-2 C₁-C₃ alkyl, C₁-C₃ alkoxy or halo groups;

R⁸ is hydrogen or C₁-C₃ alkyl;

or a pharmaceutically acceptable salt thereof, *in a preparation of a medicament for affecting the serotonin 1A receptor in a subject in need thereof.*

10 32. A ^{Use}method of Claim 31 wherein the compound is a compound wherein r is 1-3, s is 0, X is hydrogen or hydroxy, and D completes a pyrrolyl group.

33. A ^{Use}method of Claim 32 wherein the compound is a compound wherein R is of Formula III or Formula V.

15 34. A ^{Use}method of Claim 33 wherein the compound is a compound wherein R is of Formula V and A is of Formula VIII.

35. A ^{Use}method of Claim 34 wherein the compound is a compound wherein M completes a benzopyranyl, benzodihydropyranyl, naphthodihydrofuranyl, benzodihydrofuranyl, indanyl, indenyl or tetralinyl group, substituted with 0-2 C₁-C₃ alkyl, oxo, C₁-C₃ alkoxy, pyrrolidinyl- or piperidinyl-C₁-C₃ alkoxy, C₁-C₂ alkylenedioxy, phenoxy, benzyloxy, phenyl or halo groups.

25 36. A ^{Use}method of Claim 35 wherein the compound is a compound wherein M completes a group which is substituted with 0-2 alkyl, alkoxy, oxo, phenyl, halo, phenoxy or benzyloxy groups.

30 37. A ^{Use}method of Claim 33 wherein the compound is a compound wherein R is of Formula III and R³ is benzodioxolyl or benzodioxinyl; or R³ is phenyl, naphthyl, indolyl or benzothienyl,

substituted with 0-2 C₁-C₃ alkyl, C₁-C₃ alkoxy, C₄-C₈ cycloalkylalkoxy, halo, nitro, trifluoromethyl, difluoromethyl, hydroxy or trifluoromethoxy groups;

35

-215-

or substituted with 0-1 phenyl, piperidinonyl, hexahydropyridazinonyl or piperazinonyl group, substituted with 0-2 C₁-C₃ alkyl, oxo, C₁-C₃ alkoxy, halo or trifluoromethyl groups.


5 38. A ^{Use}method of Claim 31 wherein the compound is (2S)-(-)-1-(4-indolyloxy)-3-(4-(3,4-methylenedioxy)phenyl)-piperidin-1-yl)-2-propanol, (2S)-(-)-1-(4-indolyloxy)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-2-propanol or (2S)-(-)-1-(4-indolyloxy)-3-(5-methoxyspiro[benzodihydrofuran-1(3H),4'-piperidin]-1'-yl)-2-propanol or a pharmaceutically acceptable salt thereof.

39. A ^{Use}method of Claim 31 wherein the compound is (2S)-(-)-1-(4-indolyloxy)-3-(4-(3,4-ethylenedioxy)phenyl)-piperidin-1-yl)-2-propanol, (2S)-(-)-1-(4-indolyloxy)-3-(3,4-dihydro-2-oxospiro[naphthalene-1(2H),4'-piperidin]-1'-yl)-2-propanol or (2S)-(-)-1-(4-indolyloxy)-3-(4-methoxyspiro[benzodihydrofuran-1(3H),4'-piperidin]-3-one-1'-yl)-2-propanol or a pharmaceutically acceptable salt thereof.

40. A ^{Use}method of Claim 31 wherein the compound is (2S)-(-)-1-(4-indolyloxy)-3-(4-methoxyspiro[benzodihydrofuran-1(3H),4'-piperidin]-1'-yl)-2-propanol, 1-(4-indolyloxy)-3-(4-methoxyspiro[benzodihydrofuran-1(3H),4'-piperidin]-1'-yl)propane or (2S)-(-)-1-(4-indolyloxy)-3-(5-methylspiro[benzodihydrofuran-1(3H),4'-piperidin]-1'-yl)-2-propanol or a pharmaceutically acceptable salt thereof.

41. A ^{Use of}~~method of inhibiting the reuptake of serotonin which comprises administering to a subject in need of such treatment~~ an effective amount of a compound of formula

-216-




XIII


wherein r is 0-3;

X is hydrogen or hydroxy;

5 R is



III



IV

or



V

10 the dotted line is an optional double bond;

R² is hydroxy or hydrogen, or is absent when the dotted line is a double bond;

R³ is C₁-C₄ alkyl,

substituted with 1-2 phenyl groups,

15 substituted with 0-2 halo groups;

or R³ is dibenzocycloheptenyl or benzodioxinyl;

or R³ is phenyl, benzothienyl, naphthyl, indolyl or piperidino,

substituted with 0-2 C₁-C₃ alkoxy, hydroxy, cyano, C₁-C₃

20 alkyl, C₄-C₈ cycloalkylalkoxy, halo, nitro,

trifluoromethyl or trifluoromethoxy groups;

or R² and R³ combine to form C₁-C₄ alkylidene,

substituted with 1-2 phenyl groups,

substituted with 0-2 halo groups;


25 R⁵ is phenyl, phenyl-C₁-C₃ alkyl, or diphenyl-C₁-C₃ alkyl,

substituted with 1-2 halo, C₁-C₃ alkoxy or

trifluoromethyl groups;

-217-

A is a residue which combines with the nitrogen atom to which it is attached to complete



VIII

M is a residue which combines with the carbon atom to which it is attached to complete a benzopyranyl, naphthodihydrofuranyl, benzodihydrothienyl, or benzodihydrofuranyl group, wherein the spiro junction is not to an aromatic ring, substituted with 0-2 C₁-C₃ alkoxy, benzyloxy, phenyl or halo groups;

or a pharmaceutically acceptable salt thereof, in a preparation of a medicament for inhibiting the reuptake of serotonin in a subject in need thereof.

42. A ^{use}method of Claim 41 wherein the serotonin 1A receptor of the subject is also affected by the compound.

43. A ^{use}method of Claim 42 wherein the compound is a compound wherein r is 1-2.

44. A ^{use}method of Claim 43 wherein R is of Formula III or Formula V and A is of Formula VIII.

45. A ^{use}method of Claim 44 wherein the compound is a compound wherein R is of Formula III, and R³ is phenyl, naphthyl, benzothienyl or indolyl,

substituted with 0-2 C₁-C₃ alkoxy, C₁-C₃ alkyl, C₄-C₈ cycloalkylalkoxy, halo, nitro, trifluoromethyl or trifluoromethoxy groups.

46. A ^{use}method of Claim 44 wherein the compound is a compound wherein A is of Formula VIII and M completes a naphthodihydrofuranyl or benzodihydrofuranyl group, substituted with 0-2 C₁-C₃ alkoxy, benzyloxy, phenyl or halo groups.

47. A ^{use}method of Claim 45 wherein the compound is a compound wherein R³ is indolyl or benzothienyl, substituted with 1-2 C₁-C₃ alkoxy, C₁-C₃ alkyl, C₄-C₈ cycloalkylalkoxy, halo, nitro, trifluoromethyl or trifluoromethoxy groups.

-218-

48. A ^{use}~~method~~ of Claim 42 wherein the compound is (2S)-(-)-1-(4-indolyloxy)-3-(4-(2-naphthyl)piperidin-1-yl)-2-propanol, (2S)-(-)-1-(4-indolyloxy)-3-(benzo[e]spiro-[benzodihydrofuran-1(3H),4'-piperidin]-1'-yl)-2-propanol or
5 (2S)-(+)-3-[4-(7-chloro-3-indolyl)-piperidin-1-yl]-1-(4-indolyloxy)-2-propanol or a pharmaceutically acceptable salt thereof.

49. A ^{use}~~method~~ of Claim 42 wherein the compound is 3-[4-(6-chloro-3-indolyl)piperidin-1-yl]-1-(4-indolyloxy)propane,
10 3-[4-(6-chloro-3-indolyl)-1,2,3,6-tetrahydropyridin-1-yl]-1-(4-indolyloxy)-2-propanol or 3-[4-(6-nitro-3-indolyl)-1,2,3,6-tetrahydropyridin-1-yl]-1-(4-indolyloxy)propane or a pharmaceutically acceptable salt thereof.

50. A ^{use}~~method~~ of Claim 42 wherein the compound is (2S)-
15 (-)-3-[4-(6-nitro-3-indolyl)-1,2,3,6-tetrahydropyridin-1-yl]-1-(4-indolyloxy)-2-propanol or (2S)-(-)-3-[4-(6-trifluoromethyl-3-indolyl)piperidin-1-yl]-1-(4-indolyloxy)-2-propanol or a pharmaceutically acceptable salt thereof.

51. A ^{use}~~method~~ ^{comprising the use of Claim 31 for} of preventing or alleviating the symptoms
20 caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine, ~~which comprises the method of Claim 31.~~

52. A ^{use}~~method~~ of Claim 51 wherein the compound is a compound wherein r is 1-3, s is 0, X is hydrogen or hydroxy,
25 and D completes a pyrrolyl group.

53. A ^{use}~~method~~ of Claim 52 wherein the compound is a compound wherein R is of Formula III or Formula V.

54. A ^{use}~~method~~ of Claim 53 wherein the compound is a compound wherein R is of Formula V and A is of Formula VIII.

55. A ^{use}~~method~~ of Claim 54 wherein the compound is a
30 compound wherein M completes a benzopyranyl, benzodihydropyranyl, naphthodihydrofuranyl, benzodihydrofuranyl, indanyl, indenyl or tetralinyl group, substituted with 0-2 C₁-C₃ alkyl, oxo, C₁-C₃ alkoxy, pyrrolidinyl- or piperidinyl-C₁-C₃ alkoxy, C₁-C₂
35 alkylenedioxy, phenoxy, benzyloxy, phenyl or halo groups.

-219-

56. A ^{use}method of Claim 55 wherein the compound is a compound wherein M completes a group which is substituted with 0-2 alkyl, alkoxy, oxo, phenyl, halo, phenoxy or benzyloxy groups.

57. A ^{use}method of Claim 53 wherein the compound is a compound wherein R is of Formula III and R³ is benzodioxolyl or benzodioxinyl; or R³ is phenyl, naphthyl, indolyl or benzothienyl,

substituted with 0-2 C₁-C₃ alkyl, C₁-C₃ alkoxy, C₄-C₈ cycloalkylalkoxy, halo, nitro, trifluoromethyl, difluoromethyl, hydroxy or trifluoromethoxy groups; or substituted with 0-1 phenyl, piperidinonyl, hexahydropyridazinonyl or piperazinonyl group,

substituted with 0-2 C₁-C₃ alkyl, oxo, C₁-C₃ alkoxy, halo or trifluoromethyl groups.

58. A ^{use}method of Claim 51 wherein the compound is (2S)-(-)-1-(4-indolyloxy)-3-(4-(3,4-methylenedioxy)phenyl)-piperidin-1-yl)-2-propanol, (2S)-(-)-1-(4-indolyloxy)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-2-propanol or (2S)-(-)-1-(4-indolyloxy)-3-(5-methoxyspiro[benzodihydrofuran-1(3H),4'-piperidin]-1'-yl)-2-propanol or a pharmaceutically acceptable salt thereof.

59. A ^{use}method of Claim 51 wherein the compound is (2S)-(-)-1-(4-indolyloxy)-3-(4-(3,4-ethylenedioxy)phenyl)-piperidin-1-yl)-2-propanol, (2S)-(-)-1-(4-indolyloxy)-3-(3,4-dihydro-2-oxospiro[naphthalene-1(2H),4'-piperidin]-1'-yl)-2-propanol or (2S)-(-)-1-(4-indolyloxy)-3-(4-methoxyspiro[benzodihydrofuran-1(3H),4'-piperidin]-3-one-1'-yl)-2-propanol or a pharmaceutically acceptable salt thereof.

60. A ^{use}method of Claim 51 wherein the compound is (2S)-(-)-1-(4-indolyloxy)-3-(4-methoxyspiro[benzodihydrofuran-1(3H),4'-piperidin]-1'-yl)-2-propanol, 1-(4-indolyloxy)-3-(4-methoxyspiro[benzodihydrofuran-1(3H),4'-piperidin]-1'-yl)propane or (2S)-(-)-1-(4-indolyloxy)-3-(5-methylspiro[benzodihydrofuran-1(3H),4'-piperidin]-1'-yl)-2-propanol or a pharmaceutically acceptable salt thereof.

-220-

^{use} comprising the use of Claim 41 for

61. A ~~method~~^{use} of treating depression, ~~which comprises the method of Claim 41.~~

62. A ~~method~~^{use} of Claim 61 wherein the compound is a compound wherein r is 1-2.

5 63. A ~~method~~^{use} of Claim 62 wherein the compound is a compound wherein R is of Formula III or Formula V and A is of Formula VIII.

64. A ~~method~~^{use} of Claim 63 wherein R is of Formula V, A is of Formula VIII and M completes a naphthodihydrofuranyl or
10 benzodihydrofuranyl group,
substituted with 0-2 C₁-C₃ alkoxy, benzyloxy, phenyl or halo groups.

65. A ~~method~~^{use} of Claim 63 wherein the compound is a compound wherein R is of Formula III and R³ is phenyl,
15 naphthyl, benzothienyl or indolyl,
substituted with 0-2 C₁-C₃ alkoxy, C₁-C₃ alkyl, C₄-C₈ cycloalkylalkoxy, halo, nitro, trifluoromethyl or trifluoromethoxy groups.

66. A ~~method~~^{use} of Claim 65 wherein the compound is a
20 compound wherein R³ is benzothienyl or indolyl,
substituted with 0-2 C₁-C₃ alkoxy, C₁-C₃ alkyl, C₄-C₈ cycloalkylalkoxy, halo, nitro, trifluoromethyl or trifluoromethoxy groups.

67. A ~~method~~^{use} of Claim 66 wherein the compound is a
25 compound wherein R³ is benzothienyl or indolyl substituted with 1-2 C₁-C₃ alkoxy, C₁-C₃ alkyl, halo, nitro, trifluoromethyl or trifluoromethoxy groups.

68. A ~~method~~^{use} of Claim 61 wherein the compound is (2S)-(-)-1-(4-indolyloxy)-3-(4-(2-naphthyl)piperidin-1-yl)-2-propanol, (2S)-(-)-1-(4-indolyloxy)-3-(benzo[e]spiro-[benzodihydrofuran-1(3H),4'-piperidin]-1'-yl)-2-propanol or (2S)-(+)-3-[4-(7-chloro-3-indolyl)-piperidin-1-yl]-1-(4-indolyloxy)-2-propanol or a pharmaceutically acceptable salt thereof.

69. A ~~method~~^{use} of Claim 61 wherein the compound is 3-[4-(6-chloro-3-indolyl)piperidin-1-yl]-1-(4-indolyloxy)propane, 3-[4-(6-chloro-3-indolyl)-1,2,3,6-tetrahydropyridin-1-yl]-1-

-221-

(4-indolyloxy)-2-propanol or 3-[4-(6-nitro-3-indolyl)-1,2,3,6-tetrahydropyridin-1-yl]-1-(4-indolyloxy)propane or a pharmaceutically acceptable salt thereof.

70. A ^{use}method of Claim 61 wherein the compound is (2S)-
5 (-)-3-[4-(6-nitro-3-indolyl)-1,2,3,6-tetrahydropyridin-1-yl]-1-(4-indolyloxy)-2-propanol or (2S)-(-)-3-[4-(6-trifluoromethyl-3-indolyl)piperidin-1-yl]-1-(4-indolyloxy)-2-propanol or a pharmaceutically acceptable salt thereof.

71. A ^{use}method ^{comprising the use of Claim 31 for} of treating anxiety, ~~which comprises the~~
10 ~~method of Claim 31.~~

72. A ^{use}method of Claim 31 wherein the compound is a compound wherein r is 1-3, s is 0, X is hydrogen or hydroxy, and D completes a pyrrolyl group.

73. A ^{use}method of Claim 72 wherein the compound is a
15 compound wherein R is of Formula III or Formula V and A is of Formula VIII.

74. A ^{use}method of Claim 73 wherein the compound is a compound wherein R³ is benzodioxolyl or benzodioxinyl; or R³ is phenyl, naphthyl, indolyl or benzothienyl,
20 substituted with 0-2 C₁-C₃ alkyl, C₁-C₃ alkoxy, C₄-C₈ cycloalkylalkoxy, halo, nitro, trifluoromethyl, difluoromethyl, hydroxy or trifluoromethoxy groups; or substituted with 0-1 phenyl, piperidinonyl, hexahydropyridazinonyl or piperazinonyl group,
25 substituted with 0-2 C₁-C₃ alkyl, oxo, C₁-C₃ alkoxy, halo or trifluoromethyl groups.

75. A ^{use}method of Claim 73 wherein R is of Formula V, A is of Formula VIII and M completes a benzopyranyl, benzodihydropyranyl, naphthodihydrofuranyl,
30 benzodihydrofuranyl, indanyl, indenyl or tetralinyl group, substituted with 0-2 C₁-C₃ alkyl, oxo, C₁-C₃ alkoxy, pyrrolidinyl- or piperidinyl-C₁-C₃ alkoxy, C₁-C₂ alkylenedioxy, phenoxy, benzyloxy, phenyl or halo groups.

76. A ^{use}method ^{comprising the use of Claim 41 for} of treating both anxiety and depression.
35 ~~which comprises the method of Claim 41.~~

77. A ^{use}method of Claim 76 wherein r is 1-2.

-222-

78. A ^{use} ~~method~~ of Claim 77 wherein the compound is a compound wherein R is of Formula III or Formula V and A is of Formula VIII.

79. A ^{use} ~~method~~ of Claim 78 wherein R is of Formula III and R³ is phenyl, naphthyl, indolyl or benzothienyl, substituted with 0-2 C₁-C₃ alkoxy, C₄-C₈ cycloalkylalkoxy, halo, nitro, trifluoromethyl or trifluoromethoxy groups.

80. A ^{use} ~~method~~ of Claim 79 wherein the compound is a compound wherein R³ is indolyl or benzothienyl, substituted with 1-2 C₁-C₃ alkoxy, C₄-C₈ cycloalkylalkoxy, halo, nitro, trifluoromethyl, or trifluoromethoxy groups.

81. A ^{use comprising the use of Claim 31 for} ~~method of~~ treating a condition chosen from the group consisting of hypertension, cognitive disorders, psychosis, sleep disorders, gastric motility disorders, sexual dysfunction, brain trauma, memory loss, eating disorders and obesity, substance abuse, obsessive-compulsive disease, panic disorder and migraine. ~~comprising the method of Claim 31.~~

82. A ^{use comprising the use of Claim 41 for} ~~method of~~ treating a condition chosen from the group consisting of obsessive-compulsive disease, obesity, migraine, pain, particularly neuropathic pain, bulimia, premenstrual syndrome or late luteal syndrome, alcoholism, tobacco abuse, panic disorder, anxiety, post-traumatic syndrome, memory loss, dementia of aging, social phobia, attention-deficit hyperactivity disorder, disruptive behavior disorders, impulsive control disorders, borderline personality disorder, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism and trichotilomania. ~~comprising the method of Claim 41.~~

83. A ^{use of a serotonin reuptake inhibitor in combination with the use of Claim 31 in a preparation of} ~~method of~~ potentiating the action of a serotonin reuptake inhibitor in increasing the availability of a medicament for serotonin, norepinephrine and dopamine in the brain, ~~comprising administering to in a subject in need of such thereof.~~ ~~treatment a serotonin reuptake inhibitor in combination with the method of Claim 31.~~

-223-

84. A ^{use}~~method~~ of Claim 51 wherein a serotonin reuptake inhibitor is also administered to the subject.